OX-MPI - Microvascular disease

Short facts  
API BI1029539
Technology -
Indication Microvascular disease
Development phase Phase 2
Expected filing with FDA -
In-house or partnership Partnership with Gesynta Pharma AB

Unmet need
Several severe microvascular complications currently have few or no approved pharmacological treatment options.

The aim
Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions.

Differentiation
More effective and/or safer than currently approved treatments.